Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option

Despite advances in treatment options, the clinical outcomes of pediatric patients with advanced solid tumors have hardly improved decades, and alternative options are urgently needed. Innovative therapies, such as chimeric antigen receptor (CAR) T cells oncolytic viruses (OVs), currently being evaluated both adults children refractory tumors. Because remarkably diverse biologically different from their adult counterparts, more research is required to develop effective regimens for these patients. Here, we first summarize recent efforts treatments Next, briefly introduce principles CAR cell therapy virotherapy trials thereof Finally, discuss basis potential benefits combining two approaches